COHBAR INC (CWBR) Stock Price, Forecast & Analysis
NASDAQ:CWBR • US19249J3077
CWBR Key Statistics, Chart & Performance
The current stock price of CWBR is 0.761 USD. In the past month the price decreased by -62.33%. In the past year, price decreased by -56.01%.
CWBR Technical Analysis
CWBR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CWBR. The financial health of CWBR is average, but there are quite some concerns on its profitability.
CWBR Financial Highlights
Over the last trailing twelve months CWBR reported a non-GAAP Earnings per Share(EPS) of -4.36. The EPS increased by 8.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -101.44% | ||
| ROE | -133.58% | ||
| Debt/Equity | 0 |
CWBR Forecast & Estimates
6 analysts have analysed CWBR and the average price target is 18.36 USD. This implies a price increase of 2312.61% is expected in the next year compared to the current price of 0.761.
CWBR Ownership
CWBR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CWBR
Company Profile
CohBar, Inc. is a clinical stage biotechnology company, which engages in the research and development of mitochondria-based therapeutics targeting chronic and age-related diseases. The company is headquartered in Menlo Park, California and currently employs 9 full-time employees. The company went IPO on 2015-01-06. The firm is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to identify and characterize the activities of these are referred to as its technology platform. Its advanced clinical candidate, CB4211, is a therapeutic for the treatment of nonalcoholic steatohepatitis and obesity. CB4211 demonstrated positive effects on reducing biomarkers of liver injury and improving metabolic homeostasis in a Phase 1a/1b clinical study in obese subjects with nonalcoholic fatty liver disease. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring MDP. CB5138 Analogs are therapeutics that have demonstrated anti-fibrotic properties in a variety of preclinical models.
Company Info
COHBAR INC
1455 Adams Drive, Suite 2050
Menlo Park CALIFORNIA 94025 US
CEO: Steven Engle
Employees: 9
Phone: 16504467888
COHBAR INC / CWBR FAQ
What does CWBR do?
CohBar, Inc. is a clinical stage biotechnology company, which engages in the research and development of mitochondria-based therapeutics targeting chronic and age-related diseases. The company is headquartered in Menlo Park, California and currently employs 9 full-time employees. The company went IPO on 2015-01-06. The firm is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to identify and characterize the activities of these are referred to as its technology platform. Its advanced clinical candidate, CB4211, is a therapeutic for the treatment of nonalcoholic steatohepatitis and obesity. CB4211 demonstrated positive effects on reducing biomarkers of liver injury and improving metabolic homeostasis in a Phase 1a/1b clinical study in obese subjects with nonalcoholic fatty liver disease. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring MDP. CB5138 Analogs are therapeutics that have demonstrated anti-fibrotic properties in a variety of preclinical models.
Can you provide the latest stock price for COHBAR INC?
The current stock price of CWBR is 0.761 USD. The price decreased by -15.44% in the last trading session.
Does COHBAR INC pay dividends?
CWBR does not pay a dividend.
What is the ChartMill technical and fundamental rating of CWBR stock?
CWBR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of COHBAR INC (CWBR) based on its PE ratio?
COHBAR INC (CWBR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.36).
What is the next earnings date for CWBR stock?
COHBAR INC (CWBR) will report earnings on 2024-03-07, after the market close.
Who owns COHBAR INC?
You can find the ownership structure of COHBAR INC (CWBR) on the Ownership tab.